Previous studies demonstrated that eIF6 is highly expressed in human cancers such as colorectal cancer, hepatocellular carcinoma, ovarian serous carcinoma, acute promyelocytic leukemia, non-small cell lung cancer, and affect lymphoma genesis and tumor progression [16–20]. Here, EIF6 is linked to ovarian serous carcinoma.